AstraZeneca to acquire TeneoTwo and its clinical-stage T-cell engager, TNB-486

In the Headlines: What if curing diseases was treated like a business?

A 25-year old idea, a concept named “the American Centers for Cures,” proposed by Lou Weisbach, a former CEO of a Fortune 500 company and a political insider, aims to shift the paradigm of research funding.

June 25, 2025

Vol.51 No.24

As Trump decimates NIH funding, a daring proposal to issue $750 billion in bonds for medical cures garners attention

As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.

FDA to issue “national priority vouchers” to companies supporting U.S. interests

A new FDA voucher program will aim to accelerate review time for applications that are deemed to be advancing U.S. “national priorities.”

June 20, 2025

Vol.51 No.24

By Claire Marie Porter

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Drugs & Targets

FDA approves tafasitamab-cxix for r/r follicular lymphoma

FDA has approved tafasitamab-cxix (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.

June 20, 2025

Vol.51 No.24